Fresenius launches suit against Gland Pharma over pain management drug patent -
In a case before the U.S. District Court for the District of New Jersey, Fresenius alleges Gland Pharma infringed on its patent for the pain management drug Naropin when Gland applied to the FDA for an ANDA for a generic product. This despite, Fresenius contends, its patent for Naropin not scheduled to expire until May 2023. According to the complaint, Gland told the FDA “that the claims of the patent-in-suit are invalid, unenforceable and/or would not be infringed” by the proposed generic.
Please see full Publication below for more information.